KELOWNA, BC, Oct. 13, 2021 /CNW/ - Avant Brands Inc
(TSX: AVNT) (OTCQX: AVTBF) (FRA: 1BUP) ("Avant" or the
"Company"), a leading producer of high quality,
handcrafted cannabis products, is pleased to announce its
financial results for the third quarter of fiscal 2021 ended
August 31, 2021 ("Q3 2021").
"We are excited to have posted two consecutive quarters of
record revenues," said Norton Singhavon, Founder and CEO of
Avant. "The Company has achieved positive momentum across three
distinct channels: recreational, medical and export. In addition,
the recent licensing of our 3PL Ventures facility in Vernon, British Columbia enables us to build
on this growth trajectory."
Key Financial Highlights (for the period ended
August 31, 2021)
All
figures are compared to the Company's most recent fiscal quarter
(Q2 2021); all financial information in this press release is
reported in Canadian dollars.
- Maintained a strong capital position with approximately
$16.3 million of cash, $26.7 million of working capital and no debt on
its balance sheet.
- Achieved record gross revenue of $3.1
million, and net revenue of $2.7
million, representing the second consecutive quarter of
record revenue.
- Sold 525 kilograms ("KG") of cannabis, compared to 394 KG, an
increase of 33%.
- Gross margin(A) increased to 40% from 39%.
- Recreational cannabis sales in Canada accounted for 71% of total sales,
compared to 92%, as the Company commenced its initial global export
shipment to Israel.
- Overall weighted average selling price decreased by 20% or
$1.43 to $5.78 per gram as the Company's export shipments
received a lower average selling price than its Canadian
recreational sales.
- Recreational weighted average selling price decreased 5% to
$6.97 per gram, as sales for Avant's
Tenzo™ brand increased with the launch of new cultivars and
packaging. The Tenzo™ brand has a lower weighted average selling
price compared to the Company's BLK MKT™ brand.
- Operating expenses(B) of $1.5
million increased by $311,000
or 25%, as the Company had various one-time non-reoccurring
expenses related to its TSX graduation and other professional
fees.
- Net loss from operations of $2.97
million, compared to a loss of $124,000, as the Company recorded a non-cash loss
of $2.3 million on fair value changes
of biological assets.
- Positive cash flow from operations (before changes in non-cash
working capital items) of $831,000,
compared to negative $512,000,
indicating significant growth within the operations.
- Adjusted EBITDA(C) loss of $267,000 compared to a
loss of $28,000.
Key Corporate Highlights
- Completed a full corporate rebrand to Avant Brands Inc. to
better align with our high-quality cannabis products, emphasize the
strength of our capabilities and raise our profile and visibility
with our customers and the investment community.
- Graduated to the Toronto Stock Exchange and strengthened the
Company's Board of Directors with the appointment of Jurgen Schreiber as Chairman of the Board,
Duane Lo as Chair of the Audit
Committee and Ruairi Twomey as
Independent Director.
- 3PL Ventures Inc., a purpose-built 60,000 sq. ft. facility
received its Standard Cultivation, Standard
Processing and Medical Sales Licences, in accordance
with Health Canada's Cannabis Act and Regulations.
- Filed preliminary base shelf prospectus for up to an aggregate
offering of $50 million to provide
the Company with the flexibility to capitalize on financing
opportunities in favourable market conditions during the 25-month
period that it remains active.
- Added to NASDAQ-listed Global X Cannabis ETF (NASDAQ: POTX),
which currently holds approximately 4.4 million shares of
Avant.
Key Sales and Market Highlights
- Successfully initiated global cannabis exports, with a first
shipment of over 200 KG of dried cannabis to Focus Medical Herbs
Ltd., a wholly owned subsidiary of IM Cannabis Corp. (NASDAQ:
IMCC).
- Continued to expand international client portfolio by signing
three additional export agreements with customers in Israel and Australia.
- BLK MKT™ continued to be a top selling premium brand in all
Canadian Provinces.
- BLK MKT™ 1G pre-rolls rapidly emerged as the top seller in
British Columbia, and experienced
an increase in market share within Ontario.
- Achieved a steady increase in B2C medical clients while
expanding the product offering in terms of cultivars (currently 11)
and package formats-sizes (currently 5).
Subsequent Events
- Enhanced the Company's portfolio of rare and unique cultivars,
with the addition of over 80 genetics, most of which are not
currently available within Canada's legal supply. The products are
expected to launch under Avant's recreational brands BLK MKT™,
Cognoscente™ and Tenzo™, during the first quarter of fiscal
2022.
- Executed manufacturing agreements with multiple extraction
companies, leveraging the Company's cultivation expertise and brand
equity, to execute its strategy within in the concentrate
segment.
- Entered into concentrates category with the debut of Tenzo™
vapes which have received strong initial feedback from the
market.
- Divested of its last non-core asset, Zenalytic Laboratories
Ltd. for a combination of cash and stock, with an aggregate value
of $300,000.
Strategic Acquisitions and Partnerships
With the recent licensing of 3PL, new roster of cultivars, and
multiple global export deals signed, the Company believes it is
well-positioned for growth over the coming quarters. Management
anticipates the Company may require further expansion or production
in order to fulfill the demands of its domestic recreational sales,
and its global exports in the near to mid-term.
The Company is actively pursuing opportunities to expand its
production output, through the acquisition of existing licensed
facilities, or contract growing of Avant's cultivars.
For parties with existing purpose-built indoor cultivation
facilities who may be interested in discussing a partnership or
acquisition, please contact the company at
connect@avantbrands.ca
Three-months
ended
|
Q3
2021
|
Q2
2021
|
Q2'21-Q3'21
% Change
|
Q3
2020
|
Q3'20-Q3-21
% Change
|
Total Gross
Revenue
|
$3,101
|
$2,904
|
7%
|
$2,400
|
29%
|
Total Net
Revenue
|
$2,730
|
$2,458
|
11%
|
$2,071
|
32%
|
Rec
Sales
|
$1,844
|
$2,390
|
-23%
|
$1,975
|
-7%
|
B2B
Sales
|
$886
|
$67
|
1220%
|
$96
|
823%
|
Gross
Margin(A) ($)
|
$1,095
|
$961
|
14%
|
$1,444
|
-24%
|
Gross
Margin(A) (%)
|
40%
|
39%
|
3%
|
70%
|
-43%
|
SG&A
|
$1,765
|
$1,453
|
21%
|
$1,161
|
52%
|
Net income (loss)
from ops
|
-$2,971
|
-$124
|
-2296%
|
$19
|
-15737%
|
Adjusted
EBITDA
|
-$267
|
-$28
|
-854%
|
$560
|
-148%
|
Adjusted EBITDA
margin
|
-9%
|
-1%
|
-793%
|
23%
|
-137%
|
Sales (KG)
|
525
|
394
|
33%
|
279
|
88%
|
Average Selling Price
$
|
$5.78
|
$7.21
|
-20%
|
$8.84
|
-35%
|
Upcoming Conference Call
Management will host a conference call to discuss the Q3 2021
results on October 14, 2021, at
5:00PM Eastern Time / 2:00PM Pacific Time.
Dial-in Information:
Canada/USA TF: 1-800-319-4610
International Toll: 1-604-638-5340
A transcript of the call will be posted on the Company's website
at www.avantbrands.ca within 48 hours of the call.
A copy of the Management Discussion & Analysis and Financial
Statements for Q3 2021 can be downloaded from the Company's SEDAR
profile, or on its website at www.avantbrands.ca.
Note (A) Gross
margin before fair value adjustments. Please refer to the Company's
Q3 2021 Financial Statements and MD&A for definitions and a
reconciliation to IFRS.
|
|
Note (B) Operating
expenses exclude non-cash items, such as depreciation and
amortization and share based payments. Please refer to the
Company's Q3 2021 Financial Statements and MD&A for definitions
and a reconciliation to IFRS.
|
|
Note (C) Adjusted
EBITDA is a non-IFRS measure and the Company calculates adjusted
EBITDA from continuing operations as net income (loss) before
interest expense, income taxes, depreciation and amortization,
unrealized gain (loss) on changes in fair value of biological
assets, equity loss on investment in associate, loss on sale of
assets, investment loss and share based payments. Management
determined that the exclusion of the fair value adjustment is an
alternative representation of performance. The fair value
adjustment is a non-cash gain (loss) and is based on fair market
value less cost to sell. The most directly comparable measure to
adjusted EBITDA (excluding fair value adjustment to biological
assets and inventory) calculated in accordance with IFRS is net
income (loss) from continuing operations. Please refer to the
Company's Q3 2021 MD&A for definitions and a reconciliation of
Adjusted EBITDA to net income (loss) from continuing
operations.
|
About Avant Brands Inc.
Avant is an innovative, market-leading premium cannabis company.
Avant has multiple licenced and operational production facilities
across Canada, which produce
high-quality, handcrafted cannabis products for our highly desired,
and award-winning consumer brands, sold across both recreational
and medical channels.
Avant's recreational consumer brands includes BLK
MKT™, Tenzo™, Cognōscente™ and Treehugger™, all
produced from rare and exceptional cultivars, and sold in
British Columbia, Ontario, Saskatchewan, Manitoba, New
Brunswick, and Yukon. The
Company's medical cannabis brand, GreenTec™, is distributed
nationwide, directly to qualified patients through
its GreenTec Medical portal, and through various medical
cannabis partners.
Avant is a publicly traded corporation listed on the Toronto
Stock Exchange (TSX: AVNT), and trades on the OTCQX Best Market
(OTCQX: AVTBF) and Frankfurt Stock Exchange (FRA: 1BUP). The
Company is headquartered in Kelowna,
British Columbia and has operations in British Columbia, Alberta and Ontario.
To learn more about Avant, to access the investor presentation,
or learn more about its consumer brands, please
visit www.avantbrands.ca.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
INFORMATION:
This news release includes certain "forward-looking
information" as defined under applicable Canadian securities
legislation, including statements regarding the plans, intentions,
beliefs and current expectations of the Company with respect to
future business activities and operating performance.
Forward-looking information is often identified by the words "may",
"would", "could", "should", "will", "intend", "plan", "anticipate",
"believe", "estimate", "expect" or similar expressions and includes
information regarding: the pursuit of opportunities to expand its
production output; and expectations for other
economic, business, and/or competitive factors. Forward-looking
information is necessarily based upon a number
of estimates and assumptions that, while considered
reasonable, are subject to known and unknown risks, uncertainties,
and other factors which may cause the actual results and future
events to differ materially from those expressed or implied by such
forward-looking information. Examples include
statements that the Company will operate in a fiscally
disciplined manner; build long-term shareholder value; reduce
operational expenses; or increase its revenue and gross
margins.
Investors are cautioned that forward-looking information is
not based on historical fact but instead reflects management's
expectations, estimates or projections concerning future results or
events based on the opinions, assumptions and estimates of
management considered reasonable at the date the statements are
made. Although the Company believes that the expectations reflected
in such forward-looking information are reasonable, such
information involves risks and uncertainties, and undue reliance
should not be placed on such information, as unknown or
unpredictable factors could have material adverse effects on future
results, performance or achievements of the Company. Among the key
factors that could cause actual results to differ materially from
those projected in the forward-looking information are the
following: regulatory and licensing risks; changes in consumer
demand and preferences; changes in general economic, business and
political conditions, including changes in the financial markets;
the global regulatory landscape and enforcement related to
cannabis, including political risks and risks relating to
regulatory change; compliance with extensive government regulation;
public opinion and perception of the cannabis industry; the impact
of COVID-19; and the risk factors set out in the Company's annual
information form dated March 16,
2021, filed with Canadian securities regulators and
available on the Company's profile on SEDAR at
www.sedar.com.
Should one or more of these risks or uncertainties
materialize, or should assumptions underlying the forward-looking
information prove incorrect, actual results may vary materially
from those described herein as intended, planned, anticipated,
believed, estimated or expected. Although the Company has attempted
to identify important risks, uncertainties and factors that could
cause actual results to differ materially, there may be others that
cause results not to be as anticipated, estimated or intended.
Accordingly, readers should not place undue reliance on
forward-looking information, which speak only as of the date
of this news release. The Company disclaims any intention or
obligation to update or revise any
forward-looking information, whether as a result
of new information, future events or otherwise, except as
required by law.
This news release refers to certain financial performance
measures that are not defined by and do not have a standardized
meaning under International Financial Reporting Standards ("IFRS")
as issued by the International Accounting Standards Board. These
non-IFRS financial performance measures are defined in the
MD&A. Non-IFRS financial measures are used by management to
assess the financial and operational performance of the Company.
The Company believes that these non-IFRS financial measures, in
addition to conventional measures prepared in accordance with IFRS,
enable investors to evaluate the Company's operating results,
underlying performance and prospects in a similar manner to the
Company's management. As there are no standardized methods of
calculating these non-IFRS measures, the Company's approaches may
differ from those used by others, and accordingly, the use of these
measures may not be directly comparable. Accordingly, these
non-IFRS measures are intended to provide additional information
and should not be considered in isolation or as a substitute for
measures of performance prepared in accordance with IFRS.
SOURCE Avant Brands Inc.